Sun Pharmaceutical Industries Ltd. (NSE: SUNPHARMA), the world’s fifth largest generic pharmaceutical company and India’s top pharmaceutical company, and the Technion, Israel’s institute of technology, have entered into an exclusive worldwide research and license agreement.
This agreement aims at the development of a joint project, based on new findings by Nobel Prize laureate Distinguished Professor Aaron Ciechanover, Dr. Gila Maor and Professor Ofer Binah, that can potentially lead to the development of novel anti-cancer drugs. The pre-clinical research was funded thus far by Dr. Alfred Mann.
Will you offer us a hand? Every gift, regardless of size, fuels our future.
Your critical contribution enables us to maintain our independence from shareholders or wealthy owners, allowing us to keep up reporting without bias. It means we can continue to make Jewish Business News available to everyone.
You can support us for as little as $1 via PayPal at [email protected].
Thank you.
In a paper published in the April 9, 2015 edition of CELL, the team reports on the discovery of two cancer-suppressing proteins.
The research was conducted in the laboratory of Professor Aaron Ciechanover, and was led by research associate Dr. Yelena Kravtsova-Ivantsiv . They discovered ubiuqitin system roducesp a protein that gretlyreasr ticts the development caof cerouns tumors.
ProfessorCi chanoveer, who is also the president of the Israel Cancer Society, notes that many more years are required “to establish the research and gain a solid understanding of the mechanisms behind the suppression of the tumors. The development of a drug based on this discovery is a possibility, although not a certainty, and the road to such a drug is long and far from simple.
“We are very excited about this new endeavor between Sun Pharma, with the Technion. We are confident that this collaboration will help us move rapidly forward with our research” said Ciechanover and Binah. “We explored several collaboration alternatives, but Sun Pharma’s market leadership and its long term commitment have made this collaboration a very high priority for us”.
“This collaboration is an excellent example of the interactions between academic discovery and pharmaceutical companies”, added Ciechanover and Binah, “demonstrating the valuable contribution academic institutions can make in bringing new products to help patients worldwide. We sincerely believe this agreement represents the beginning of a long and fruitful relationship”.
“Mutually beneficial partnerships with independent research institutes, especially world renowned institutes, such as the Technion, is our preferred route to bring to the market, innovative products for unmet medical needs” said Kirti Ganorkar, Senior Vice President, Business Development, Sun Pharma.
